Abstract:Degeneration of basal forebrain cholinergic neurons (BFCNs) in the nucleus basalis of Meynert (NBM) and vertical diagonal band (VDB) along with their connections is a key pathological event leading to memory impairment in Alzheimer's disease (AD). Aberrant neurotrophin signaling via Trks and the p75 neurotrophin receptor (p75NTR) contributes importantly to BFCN dystrophy. While NGF/TrkA signaling has received the most attention in this regard, TrkB and TrkC signaling also provide trophic support to BFCNs and these receptors may be well located to preserve BFCN connectivity. We previously identified a small molecule TrkB/TrkC ligand, LM22B-10, that promotes cell survival and neurite outgrowth in vitro and activates TrkB/TrkC signaling in the hippocampus of aged mice when given intranasally, but shows poor oral bioavailability. An LM22B-10 derivative, PTX-BD10-2, with improved oral bioavailability has been developed and this study examined its effects on BFCN atrophy in the hAPPLond/Swe (APPL/S) AD mouse model. Oral delivery of PTX-BD10-2 was started after appreciable amyloid and cholinergic pathology was present to parallel the clinical context, as most AD patients start treatment at advanced pathological stages. PTX-BD10-2 restored cholinergic neurite integrity in the NBM and VDB, and reduced NBM neuronal atrophy in symptomatic APPL/S mice. Dystrophy of cholinergic neurites in BF target regions, including the cortex, hippocampus, and amygdala, was also reduced with treatment. Finally, PTX-BD10-2 reduced NBM tau pathology and improved the survival of cholinergic neurons derived from human induced pluripotent stem cells (iPSCs) after amyloid-β exposure. These data provide evidence that targeting TrkB and TrkC signaling with PTX-BD10-2 may be an effective disease-modifying strategy for combating cholinergic dysfunction in AD. The potential for clinical translation is further supported by the compound's reduction of AD-related degenerative processes that have progressed beyond early stages and its neuroprotective effects in human iPSC-derived cholinergic neurons.

BDNF and TRiC-inspired reagent rescue cortical synaptic deficits in a mouse model of Huntington's disease

Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington's Disease

Intracerebral Transplantation of BDNF-overexpressing Human Neural Stem Cells (HB1.F3.BDNF) Promotes Migration, Differentiation and Functional Recovery in a Rodent Model of Huntington's Disease.

Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington’s disease phenotypes in R6/2 mice

Effect of Brain-Derived Neurotrophic Factor on Tyrosine Kinase B and Endogenous Brain-Derived Neurotrophic Factor Expressions by Lateral Ventricle Infusion into AD Mice

Retracted: 1H-MRS Can Monitor Metabolites Changes of Lateral Intraventricular BDNF Infusion into a Mouse Model of Alzheimer’s Disease in Vivo [neuroscience 245 (2013) 40–49]

1H-MRS Assessment of the Therapeutic Effect of Bilateral Intraventricular BDNF Infusion into APP/PS1 Double Transgenic Mice

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Enhancement of Brain-Type Creatine Kinase Activity Ameliorates Neuronal Deficits in Huntington's Disease

Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

Impairments in High-Frequency Transmission, Synaptic Vesicle Docking, and Synaptic Protein Distribution in the Hippocampus of Bdnf Knockout Mice

Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage

Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice

Modulating glial genes involved in synaptic function mitigates pathogenesis and behavioral deficits in a<i>Drosophila</i>model of Huntington’s Disease

Environmental Enrichment Rescues Protein Deficits in a Mouse Model of Huntington's Disease, Indicating a Possible Disease Mechanism

Reduced Lysosomal Density in Neuronal Dendrites Mediates Deficits in Synaptic Plasticity in Huntington’s Disease

Enhanced Store-Operated Calcium Entry Leads To Striatal Synaptic Loss In A Huntington'S Disease Mouse Model

CryoET reveals organelle phenotypes in huntington disease patient iPSC-derived and mouse primary neurons

Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis

Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease